Abstract
Viruses have been engineered to replicate selectively in cancer cells, based on a number of innovative principles. Several of these viruses have entered clinical trials and have proven relatively safe, and have shown evidence of efficacy. However, further research is required to enable these agents to function systemically. This might involve attempts to suppress immune responses to virus antigens, and re-targeting of viruses to favor tumor infection and increased potency. When these barriers are overcome, oncolytic viruses could enter the mainstream of clinical oncology,
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Aghia M and Martuza RL . (2005). Oncogne, x, x–x (this issue).
Fueyo J, Alemany R, Gomez-Manzano C, Fuller GN, Khan A, Conrad CA, Liu T-J, Lemoine MG, Suzuki K, Sawaya R, Curiel DT, Yung WKA and Lang FF . (2003). J. Natl. Cancer Inst., 95, 652–660.
Heise C, Hermiston T, Johnson L, Brooks G, Sampson-Johannes A, Williams A, Hawkins L and Kirn D . (2000). Nat. Med., 6, 1134–1139.
Johnson L, Shen A, Boyle L, Kunich J, Pandey K, Lemmon M, Hermiston T, Giedlin M, McCormick F and Fattaey A . (2002). Cancer Cell, 1, 325–337.
Ko D, Hawkins L and Yu DC . (2005). Oncogene, x, x–x (this issue).
McCormick F . (2001). Nat. Rev. Cancer, 1, 130–141.
Nemunaitis J and Edelman J . (2002). Cancer Gene Ther., 9, 987–1000.
O'Shea CC, Johnson L, Bagus B, Choi S, Nicholas C, Shen A, Boyle L, Pandey K, Soria C, Shen Y, Habets G, Ginzinger D and McCormick F . (2004). Cancer Cell, 6, 611–623.
Reid T, Warren R and Kirn D . (2002). Cancer Gene Ther., 9, 979–986.
Reid T, Galeris E, Abbruzzese J, Sze D, Andrews J, Romel L, Hatfield M, Rubin J and Kirn D . (2001). Gene Therapy, 8, 1618–1626.
Yu C, DeWeeese T, Dilley J, Zhang Y, Li Y, Ramesh N, Lee J, Pennathur-Das R, Radzyminski J, Wypych J, Brignetti D, Scott S, Stephens J, Karpf D, Henderson DR and Yu D-C . (2001). Cancer Res., 61, 5453–5460.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
McCormick, F. Future prospects for oncolytic therapy. Oncogene 24, 7817–7819 (2005). https://doi.org/10.1038/sj.onc.1209064
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1209064
Keywords
This article is cited by
-
Efficient virotherapy of cancer in the presence of immune response
International Journal of Dynamics and Control (2014)
-
Oncolytic Adenovirus Expressing Soluble TGFβ Receptor II-Fc-mediated Inhibition of Established Bone Metastases: A Safe and Effective Systemic Therapeutic Approach for Breast Cancer
Molecular Therapy (2011)
-
The viral tropism of two distinct oncolytic viruses, reovirus and myxoma virus, is modulated by cellular tumor suppressor gene status
Oncogene (2010)
-
A modified hTERT promoter-directed oncolytic adenovirus replication with concurrent inhibition of TGFβ signaling for breast cancer therapy
Cancer Gene Therapy (2010)
-
A strategy for systemic delivery of the oncolytic herpes virus HSV1716: redirected tropism by antibody-binding sites incorporated on the virion surface as a glycoprotein D fusion protein
Gene Therapy (2008)
